Pulmonx now sits under a reset US$5 price target, with the fair value estimate holding at US$5.17 per share, signalling that the core valuation framework has not been reworked. Bullish analysts see ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial ...

Glen French, member of the Board of Directors and former Pulmonx President and Chief Executive Officer, reappointed President and Chief Executive Officer Derrick Sung, former Pulmonx Chief Financial ...

REDWOOD CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that ...

Glendon French, President and Chief Executive Officer, and Derrick Sung, Chief Operating Officer and Chief Financial Officer. Earlier today, Pulmonx Corporation issued a press release announcing its ...

Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2026 ...

REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today ...

REDWOOD CITY, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will ...

REDWOOD CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will ...

Approval of First Minimally Invasive Treatment Option in Japan that Helps Patients with Advanced Disease Breathe Easier and Have a Better Quality of Life Over 600,000 Japanese patients suffer from ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be ...

Pulmonx Corp. set terms for its initial public offering, in which the California-based medical technology company that provides treatment for emphysema looks to raise up to $106.7 million. The company ...